Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK16149 Long-term Safety in Peripheral Neuropathic Pain
CTR20213431Phase 3Completed
- Sponsor
- Sichuan Haisco Pharmaceutical Co., Ltd.
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of crisugabalin besilate in Peripheral neuropathic pain and diabetic polyneuropathy (DPN), sponsored by Sichuan Haisco Pharmaceutical Co., Ltd. Primary endpoint: Adverse events and safety assessments over 53 weeks. Started Jan 2022; status: completed.
02
Drugs
crisugabalin besilate
03
Conditions
Peripheral neuropathic paindiabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on CTR20213431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213431.